Mesoblast (MESO) Other Non-Current Assets (2015 - 2026)
Mesoblast (MESO) posted Other Non-Current Assets of $1.2 million for Q4 2025, down 7.87% sequentially from $1.3 million in Q2 2025, and down 10.43% YoY from $1.3 million in Q4 2024.
Analysis
Mesoblast (MESO) Other Non-Current Assets (2015 - 2026) Analysis & Trends
Mesoblast has reported Other Non-Current Assets for 11 years, with the latest figure at $1.2 million in Q4 2025.
- Quarterly Other Non-Current Assets fell 10.43% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 10.43% YoY) and the FY2025 annual result came in at $1.3 million, down 38.34% from the prior year.
- Other Non-Current Assets retreated to $1.2 million in Q4 2025 per MESO's latest filing, from $1.3 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.2 million in Q1 2021 and troughed at $1.2 million in Q4 2025.
- A 5-year average of $2.0 million and a median of $2.0 million in 2021 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2023: Other Non-Current Assets tumbled 47.93% in 2021, then grew 21.03% in 2023.
- Over 5 years, Other Non-Current Assets stood at $2.0 million in 2021, then dropped by 1.74% to $1.9 million in 2022, then rose by 16.6% to $2.2 million in 2023, then sank by 40.52% to $1.3 million in 2024, then decreased by 10.43% to $1.2 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.2 million, $1.3 million, and $1.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 1.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Dec 31, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Jun 30, 2024 | 397,000.00 |
| Dec 31, 2023 | 2.24 Mn |
| Jun 30, 2023 | 398,000.00 |
| Mar 31, 2023 | 2.39 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Sep 30, 2022 | 1.90 Mn |
| Jun 30, 2022 | 413,000.00 |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 1.95 Mn |
| Jun 30, 2021 | 451,000.00 |
| Mar 31, 2021 | 3.20 Mn |
| Dec 31, 2020 | 3.21 Mn |
| Sep 30, 2020 | 3.33 Mn |
| Jun 30, 2020 | 3.31 Mn |
| Mar 31, 2020 | 3.24 Mn |